Supplementary figure 2.

A

ACA8

MTSLLKSSPGRRRGGDVESGKSEHADSDSDTFYIPSKNASIERLQQWRKAALVLNASRRFRYTLDLKKEQE
TREMRQKIRSHAHALLAANRFMDMGRESGVEKTTGPATPAGDFGITPEQLVIMSKDHNSGALEQYGGTQGL
ANLLKTNPEKGISGDDDDLLKRKTIYGSNTYPRKKGKGFLRFLWDACHDLTLIILMVAAVASLALGIKTEG
IKEGWYDGGSIAFAVILVIVVTAVSDYKQSLQFQNLNDEKRNIHLEVLRGGRRVEISIYDIVVGDVIPLNI
GNQVPADGVLISGHSLALDESSMTGESKIVNKDANKDPFLMSGCKVADGNGSMLVTGVGVNTEWGLLMASI
SEDNGEETPLQVRLNGVATFIGSIGLAVAAAVLVILLTRYFTGHTKDNNGGPQFVKGKTKVGHVIDDVVKV
LTVAVTIVVVAVPEGLPLAVTLTLAYSMRKMMADKALVRRLSACETMGSATTICSDKTGTLTLNQMTVVES
YAGGKKTDTEQLPATITSLVVEGISQNTTGSIFVPEGGGDLEYSGSPTEKAILGWGVK|LGMNFETARSQS
SILHAFPFNSEKKRGGVAVKTADGEVHVHWKGASEIVLASCRSYIDEDGNVAPMTDDKASFFKNGINDMAG
RTLRCVALAFRTYEAEKVPTGEELSKWVLPEDDLILLAIVGIKDPCRPGVKDSVVLCQNAGVKVRMVTGDN
VQTARAIALECGILSSDADLSEPTLIEGKSFREMTDAERDKISDKISVMGRSSPNDKLLLVQSLRRQGHVV
AVTGDGTNDAPALHEADIGLAMGIAGTEVAKESSDIIILDDNFASVVKVVRWGRSVYANIQKFIQFQLTVN
VAALVINVVAAISSGDVPLTAVQLLWVNLIMDTLGALALATEPPTDHLMGRPPVGRKEPLITNIMWRNLLI
QAIYQVSVLLTLNFRGISILGLEHEVHEHATRVKNTIIFNAFVLCQAFNEFNARKPDEKNIFKGVIKNRLF
MGIIVITLVLQVIIVEFLGKFASTTKLNWKQWLICVGIGVISWPLALVGKFIPVPAAPISNKLKVLKFWGK
KKNSSGEGSL

ACA10

MSGQFNNSPRGEDKDVEAGTSSFTEYEDSPFDIASTKNAPVERLRRWRQAALVLNASRRFRYTLDLKREED
KKQMLRKMRAHAQAIRAAHLFKAAASRVTGIASPLPTPGGGDFGIGQEQIVSISRDQNIGALQELGGVRGL
SDLLKTNLEKGIHGDDDDILKRKSAFGSNTYPQKKGRSFWRFVWEASQDLTLIILIVAAVASLALGIKTEG
IEKGWYDGISIAFAVLLVIVVTATSDYRQSLQFQNLNEEKRNIRLEVTRDGRRVEISIYDIVVGDVIPLNI
GDQVPADGVLVAGHSLAVDESSMTGESKIVQKNSTKHPFLMSGCKVADGNGTMLVTGVGVNTEWGLLMASV
SEDNGGETPLQVRLNGVATFIGIVGLTVAGVVLFVLVVRYFTGHTKNEQGGPQFIGGKTKFEHVLDDLVEI
FTVAVTIVVVAVPEGLPLAVTLTLAYSMRKMMADKALVRRLSACETMGSATTICSDKTGTLTLNEMTVVEC
YAGLQKMDSPDSSSKLPSAFTSILVEGIAHNTTGSVFR|SESGEIQVSGSPTERAILNWAIKLGMDFDALK
SESSAVQFFPFNSEKKRGGVAVKSPDSSVHIHWKGAAEIVLGSCTHYMDESESFVDMSEDKMGGLKDAIDD
MAARSLRCVAIAFRTFEADKIPTDEEQLSRWELPEDDLILLAIVGIKDPCRPGVKNSVLLCQQAGVKVRMV
TGDNIQTAK|AIALECGILASDSDASEPNLIEGKVFRSYSEEEERDRICEEISVMGRSSPNDKLLLVQSLKR
RGHVVAVTGDGTNDAPALHEADIGLAMGIQGTEVAKEKSDIIILDDNFESVVKVVRWGRSVYANIQKFIQF
QLTVNVAALVINVVAAISAGEVPLTAVQLLWVNLIMDTLGALALATEPPTDHLMDRAPVGRREPLITNIMW
RNLFIQAMYQVTVLLILNFRGISILHLKSKPNAERVKNTVIFNAFVICQVFNEFNAR|KPDEINIFRGVLR
NHLFVGIISITIVLQVVIVEFLGTFASTTKLDWEMWLVCIGIGSISWPLAVIGKLIPVPETPVSQYFRINR
WRRNSSG

B

protein	peptide sequence	n peptide	occurrence[a]	best mascot score
ACA8				
	SHAHALLAANR	4	2/6 - (0/3)	66.4
	DHNSGALEQYGGTQGLANLLK	1	1/6 - (0/3)	43.1
	GISGDDDDLLK	1	1/6 - (0/3)	39.3
	NIHLEVLR	3	3/6 - (0/3)	32.1
	AILGWGVK	1	1/6 - (0/3)	31.7
	LGMNFETAR	1	1/6 - (0/3)	61.7
	TYEAEKVPTGEELSK	5	5/6 - (0/3)	78.4
	DSVVLCQNAGVK	1	1/6 - (0/3)	52.2
	MVTGDNVQTAR	4	3/6 - (0/3)	91.3
	FIPVPAAPISNK	2	2/6 - (0/3)	39.3
ACA10				
	DQNIGALQELGGVR	5	5/6 - (0/3)	108.9
	GIHGDDDDILK	3	3/6 - (0/3)	55.7
	SAFGSNTYPQKK	3	3/6 - (0/3)	42.3
	LPSAFTSILVEGIAHNTTGSVFR	1	1/6 - (0/3)	46.7
	SESGEIQVSGSPTER	6	6/6 - (0/3)	68.2
	MVTGDNIQTAK	7	6/6 - (0/3)	62.2
	AIALECGILASDSDASEPNLIEGK	1	1/6 - (0/3)	77.1
	SSPNDKLLLVQSLK	2	2/6 - (0/3)	71
	VKNTVIFNAFVICQVFNEFNAR	1	1/6 - (0/3)	52.8
	KPDEINIFR	1	1/6 - (0/3)	44.6
	LIPVPETPVSQYFR	2	2/6 - (0/3)	57.1

Figure S2. Identification of ACA8 and ACA10 peptides by mass-spectrometry analysis of immuno-purified FLS2-GFP. 21 *in vitro* grown seedlings were used either untreated or treated with flg22. Sample preparations, immuno-purifications and MS/MS analysis were performed essentially as described in Roux et al. (2011). Briefly, immuno-purifications of GFP-tagged proteins were done using the magnetic GFP-trap system from Miltenyi Biotech using an IGEPAL-solubilised protein extract (4 mg protein per mL). Beads were washed with 0.1% IGEPAL extraction buffer prior to elution in boiling Laemli buffer. **A.** Peptide coverage of ACA8 and ACA10 proteins identified in an FLS2-GFP immuno-purified complex. Peptides found in untreated samples are highlighted in green, peptides found in flg22-elicited samples are in orange, peptides found in both conditions are indicated in blue, peptides found in all biological replicates of untreated and treated samples are shown in bold. **B.** Tryptic peptides identified by HPLC-electrospray ionization-MS/MS analysis. Peptides occurring in all biological replicates are marked in bold. Reproducibility ([a]) of specific tryptic peptides out of three biological replicates of untreated or flg22-treated samples prepared from Arabidopsis plants expressing FLS2-GFP. In brackets, no peptides were detected in technical controls using wild-type plants (n=2) or plants expressing a plasma membrane addressed GFP (Lti6b-GFP; n=1).